Rockwell Medical (RMTI) Non-Current Deffered Revenue (2016 - 2024)
Rockwell Medical's (RMTI) quarterly Non-Current Deffered Revenue came in at $429000.0 in Q4 2024, down 9.68% YoY from $475000.0 in Q1 2024, and down 2.72% on a QoQ basis from $441000.0 in Q3 2024.
Rockwell Medical (RMTI) Non-Current Deffered Revenue (2016 - 2024) Analysis & Trends
Rockwell Medical (RMTI) has 9 years of Non-Current Deffered Revenue data on file, last reported at $429000.0 in Q4 2024.
- Quarterly Non-Current Deffered Revenue fell 9.68% year-over-year to $429000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $429000.0 (down 9.68% YoY) and the FY2024 annual result came in at $429000.0, down 9.68% from the prior year.
- Non-Current Deffered Revenue retreated to $429000.0 in Q4 2024, from $441000.0 in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $9.5 million in Q1 2020 to a low of $429000.0 in Q4 2024.
- A 5-year average of $4.4 million and a median of $4.8 million in 2022 frame the typical range for Non-Current Deffered Revenue.
- Annual changes were most pronounced in 2023 — Non-Current Deffered Revenue plunged 89.33% — and 2024, when it fell 9.45%.
- Tracing RMTI's Non-Current Deffered Revenue over 5 years: stood at $8.0 million in 2020, then retreated by 25.32% to $6.0 million in 2021, then sank by 56.57% to $2.6 million in 2022, then plunged by 81.73% to $475000.0 in 2023, then fell by 9.68% to $429000.0 in 2024.
- The last three Non-Current Deffered Revenue figures came in at $429000.0 (Q4 2024), $441000.0 (Q3 2024), and $452000.0 (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | - |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Rockwell Medical | 31.73 Mn | 6.93 Mn | 3.24 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 429,000.00 |
| Sep 30, 2024 | 441,000.00 |
| Jun 30, 2024 | 452,000.00 |
| Mar 31, 2024 | 464,000.00 |
| Dec 31, 2023 | 475,000.00 |
| Sep 30, 2023 | 487,000.00 |
| Jun 30, 2023 | 2.47 Mn |
| Mar 31, 2023 | 2.54 Mn |
| Dec 31, 2022 | 2.60 Mn |
| Sep 30, 2022 | 4.57 Mn |
| Jun 30, 2022 | 5.11 Mn |
| Mar 31, 2022 | 5.46 Mn |
| Dec 31, 2021 | 5.99 Mn |
| Sep 30, 2021 | 6.53 Mn |
| Jun 30, 2021 | 6.94 Mn |
| Mar 31, 2021 | 7.48 Mn |
| Dec 31, 2020 | 8.02 Mn |
| Sep 30, 2020 | 8.56 Mn |
| Jun 30, 2020 | 8.91 Mn |
| Mar 31, 2020 | 9.45 Mn |